Spinal Muscular Atrophy Treatment Market Size

Spinal Muscular Atrophy Treatment Market size was valued at USD 7.3 billion in 2023 growing at a CAGR of 19.1% between 2024 and 2032. The key factors driving market growth include the expansion of newborn screening programs, which have led to earlier diagnoses of spinal muscular atrophy (SMA), increasing the number of patients eligible for treatment. Early diagnosis improves patient outcomes and boosts demand for medication to treat neurological conditions.

For instance, according to a report published by Health Union, LLC, SMA is one of the most common genetic conditions affecting children. One in every 6,000 to 10,000 babies worldwide is born with SMA. Type 1 SMA is the most severe form and accounts for more than half of all cases. Additionally, the prevalence of SMA is about 1 in 100,000 people globally. The prevalence is lower than the incidence due to the shorter lifespan associated with the most common SMA types. Approximately 25,000 Americans currently live with SMA. Thus, continuous advancements in diagnostic technology and increased awareness among healthcare providers and patients about SMA and its treatment options, leading to earlier interventions and higher treatment uptake, are anticipated to foster market growth.

Spinal muscular atrophy (SMA) treatment refers to medical interventions designed to manage and alleviate the symptoms of SMA, a genetic disorder characterized by the loss of motor neurons in the spinal cord, leading to muscle weakness and atrophy. Moreover, people with SMA often experience respiratory infections, scoliosis, and joint contractures (chronic shortening of muscles and tendons). While SMA primarily affects infants and children, it can also occur in adults.